Diffuse Large B-Cell Lymphoma, NOS · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	surveillance
Linked regimen	`None`

ID	`IND-OCC-PCB-PREVENTION-OBSERVATION`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB — alternative-track companion for PCB occupational prevention pilot. §15.2 C4 ≥2-tracks invariant compliance. IARC Group 2A probable — limited human evidence; clinical recommendation more conservative than Group 1; reclassified Group 1 in 2013 IARC Monograph 107 (published 2015) — authored at 2A-conservative severity per batch scope. Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode exemption.

Used By

Red flag

RF-OCC-PCB-PREVENTION - Documented historical occupational exposure to polychlorinated biphenyls (PCBs) — typical...